Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).

Schneider, Marc P.; Tornic, Jure; Sýkora, Radek; Abo Youssef, Nadim; Mordasini, Livio; Krhut, Jan; Chartier-Kastler, Emmanuel; Davies, Melissa; Gajewski, Jerzy; Schurch, Brigitte; Bachmann, Lucas M; Kessler, Thomas M (2019). Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourology and urodynamics, 38(6), pp. 1482-1491. Wiley-Liss 10.1002/nau.24039

Text Schn_Alpha blockers for treating neurogenic lower urinary tractdysfunction in patients with multiple sclerosis Asystematic review and meta analysis A report from the Neuro Urology_11119.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (924kB)

AIM

We aimed to systematically assess the evidence on the efficacy and safety of alpha-blockers in patients with multiple sclerosis (MS) suffering from neurogenic lower urinary tract dysfunction (NLUTD).

METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used to perform this systematic review. An electronic search of Cochrane register, Embase, Medline, Scopus (last search 3 March 2018) and screening of reference lists as well as reviews were used to identify the studies. Articles were included if they reported on efficacy/safety of alpha-blockers for the treatment of NLUTD in patients with MS.

RESULTS

After screening of 7'015 abstracts, three studies enrolling a total of 50 patients were included: one randomized, placebo-controlled, single-blind trial and two prospective cohort studies. Alpha-blocker treatment was successful in 50% to 96% of the patients. Pooling data from the three included studies, the relative risk for successful alpha-blocker treatment was 3.89 (95% confidence interval 2.7-7.0). The general safety profile of alpha-blockers was favorable with 8% of the patients reporting adverse events.

CONCLUSIONS

Alpha-blockers may be effective and safe for treating NLUTD in female and male patients with MS but the studies were small and the overall quality of evidence was low. To make definitive conclusions, well designed randomized controlled trials are highly warranted.

Interest & Impact

Downloads

1 since deposited on 20 Nov 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item